PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.35%
Cash & equivalents declining -35.35% while TRVN's grows 10.43%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-35.35%
Cash + STI yoy ≥ 1.5x TRVN's -19.93%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.32%
Other current assets growth < half of TRVN's -27.74%. David Dodd sees a leaner approach to short-term items.
-30.67%
≥ 1.5x TRVN's -20.31%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-13.90%
≥ 1.5x TRVN's -2.65%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Less than half of TRVN's 0.23%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-10.42%
≥ 1.5x TRVN's -2.26%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
≥ 1.5x TRVN's -17.22%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-10.38%
Less than half of TRVN's -65.95%. David Dodd sees a more disciplined AP approach or lower volume.
1404.09%
Less than half of TRVN's -35.41%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
10.38%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-3.56%
Less than half of TRVN's -35.92%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.88%
Above 1.5x TRVN's -2.07%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-5.58%
Less than half of TRVN's -23.76%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
1.25-1.5x TRVN's -1.58%. Bruce Berkowitz notes stronger reinvestment strategy.
-5.49%
Less than half of TRVN's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-43.19%
≥ 1.5x TRVN's -13.03%. David Dodd sees stronger capital base growth than competitor.
-28.48%
≥ 1.5x TRVN's -17.22%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
14.13%
Less than half of TRVN's -19.52%. David Dodd sees less overall debt expansion vs. competitor.
40.09%
Less than half of TRVN's -50.40%. David Dodd sees better deleveraging or stronger cash buildup than competitor.